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Autophagy is a cellular process of bulk degradation of
damaged organelles, protein aggregates and other
macromolecules in the cytoplasm. It is thought to be a
general response to stress contributing to cell death;
alternatively it might act as a cytoprotective mechanism.
Here we found that administration of cisplatin induced
the formation of autophagic vesicles and autophagosomes
in mouse kidneys. In cultured proximal tubular cells,
the nephrotoxin caused autophagy in a dose- and
time-dependent manner prior to apoptosis. Notably,
autophagy occurred within hours of cisplatin administration
but this was partially suppressed by the p53 inhibitor
pifithrin-a, suggesting that p53 is involved in autophagic
signaling. This cisplatin-induced autophagy was attenuated
in renal cells stably transfected with Bcl-2, suggesting an
anti-autophagic role for this well-known anti-apoptotic
protein. Blockade of autophagy with pharmacological
inhibitors (3-methyladenine or bafilomycin) or shRNA
knockdown of the autophagic gene Beclin increased tubular
cell apoptosis during cisplatin treatment. Our study has
found that autophagy occurs in acute kidney injury and this
may be an important protective mechanism for cell survival.
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Autophagy is a process of bulk degradation of damaged
organelles, protein aggregates, and other macromolecules in
the cytoplasm.1–4 At the core of autophagy is a specific family
of genes or proteins called autophagy-related gene (Atg). The
Atg proteins are responsible for initiation, formation, and
maturation of autophagosomes, which subsequently fuses
with lysosomes for hydrolysis or degradation of enwrapped
materials.1–4 Atgs were originally identified in yeast, but their
mammalian orthologs are now being discovered and shown
to play critical roles in autophagy in mammalian cells and
animals.1–4 For example, Beclin-1, the mammalian ortholog
of yeast Atg6, contributes to vesicle nucleation, an early event
for autophagosome formation.5 LC3, the mammalian
ortholog of Atg8, is proteolytically processed and conjugated
with phosphotidylethanolamine to form LC3-II, which is
then localized on the autophagic vesicle for its elongation and
expansion.6
Traditionally, autophagy is recognized as a cellular
response to nutrient deprivation or starvation, whereby cells
digest a portion of cytoplasm to recycle nutrients for survival.
However, recent studies have suggested that autophagy might
be a general cellular response to stress.1–4 Depending on the
experimental conditions, autophagy can directly induce cell
death or act as a mechanism of cytoprotection. Despite recent
rapid progress in autophagy research, very little is known
about autophagy in renal cells, tissues or systems.
Acute kidney injury by ischemia, sepsis, or nephrotoxins is
a typical condition of renal stress, leading to cell death, tissue
damage, and loss of renal function or renal failure.7–11 Is
autophagy induced during acute kidney injury? Does
autophagy contribute to renal cell injury and death, or
survival under this pathological condition? This study was
designed to address these questions by using experimental
models of cisplatin nephrotoxicity. Cisplatin is a widely used
chemotherapy drug, with major side effects in kidneys,
inducing acute kidney injury.12,13 While multiple mecha-
nisms have been documented to contribute to cisplatin
nephrotoxicity,14–33 how these signaling pathways are inte-
grated to induce renal pathology is largely unknown.13 Here
we demonstrate early occurrence of autophagy during
cisplatin treatment of renal tubular cells and tissues.
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Importantly, autophagy appears to be a cytoprotective
mechanism for cell survival.
RESULTS
Autophagy is induced early during cisplatin treatment,
prior to tubular cell apoptosis and renal injury
To determine the occurrence of autophagy during cisplatin
nephrotoxicity, we examined an in vitro model of cultured
proximal tubular cells (RPTC). This model has been
characterized in previous studies.16–18 Our initial analysis
was focused on subcellular localization and redistribution of
LC3, because redistribution of LC3 from cytosol to a punctate
autophagosome staining is an indication of autophagy.34
To this end, cells were transfected with a green fluorescent
protein (GFP)-LC3 fusion plasmid and then treated with
20 mM cisplatin for 0–16 h, followed by examination by
fluorescence microscopy. In the control group, 27% of
transfected (GFP-labeled) cells had punctate LC3 staining. Six
hours of cisplatin treatment increased the percentage of LC3
punctate cells toB50% (Figure 1a). Further incubation with
cisplatin to 12 or 16 h led to gradual disappearance of LC3
puncta, an observation that was consistent with the degra-
dation of LC3 in matured autophagosomes (Figure 1a).
Representative LC3 staining in control and cisplatin-treated
cells is shown in Figure 1b. By analyzing LC3 redistribution,
we further showed that induction of autophagy was
dependent on cisplatin dose (Figure 1b). Significant increases
of autophagic (LC3 punctate) cells were induced by 5–20 mM,
but not 1 or 2 mM, cisplatin (Figure 1c). To further analyze
autophagy, we examined formation of LC3-II, the autophagic
form of LC3.35 RPTCs were incubated with 20 mM cisplatin
for 0–16 h to collect whole-cell lysates for immunoblot
analysis. As shown in Figure 1d, cisplatin induced an
obvious accumulation of LC3. Of note, LC3-II, the
autophagic form, showed highest accumulation at 6 h of
cisplatin treatment and then decreased toward basal levels
(Figure 1d), which correlated with the time course of
punctate LC3 formation (Figure 1a). As shown in our
previous work,16–18 cisplatin at 20 mM induced significant
amounts of apoptosis in RPTCs in a time-dependent manner
(Figure 1e). It is noteworthy that occurrence of autophagy
was hours earlier than apoptosis (Figures 1a and e). The
results suggest that cisplatin-induced autophagy is not caused
by or secondary to apoptosis.
We further verified cisplatin-induced autophagy in RPTCs
by electron microscopy. As shown by representative micro-
graphs, autophagosomes with characteristic double or multi-
ple membranes were identified in the cells after 6 h of
cisplatin treatment (Figure 2a, arrows). In addition, there
were many autophagic vacuoles or vesicles (Figure 2a,
arrowheads). Counting autophagic vesicles in the micro-
graphs also indicated higher autophagy in cisplatin-treated
cells (Figure 2b). Interestingly, these cells also showed
autophagic vesicles at different stages of autophagosome
apparently from initiation, elongation, complete assembly, to
maturation (Figure 2c–g).
Autophagy during cisplatin nephrotoxicity in C57BL/6 mice
To gain initial evidence for autophagy during cisplatin
nephrotoxicity in vivo, C57BL/6 mice were injected with a
single dose of 30 mg/kg cisplatin.28,36,37 We first examined
autophagy by electron microscopy. As shown in Figure 3a,
2 days after cisplatin injection, numerous vacuoles appeared
in some proximal tubular cells and some of the vacuoles
contained cytosolic materials, becoming autophagic vesicles
(arrow). At day 3, the numbers of empty vacuoles decreased,
but their sizes increased. In addition, more vesicles had taken
up cytosolic materials to become autophagosomes (arrow).
Counting cells containing autophagic vacuoles or vesicles
showed progressive increase of autophagy during cisplatin
nephrotoxicity (Figure 3b). By the end of 2–3 days of cisplatin
treatment, over 30% of renal tubular cells were auto-
phagic. To further confirm autophagy, we collected renal
tissue lysates for immunoblot analysis of LC3. As shown in
Figure 3c, there was a notable increase of LC3-II in renal
tissues following cisplatin injection, particularly at day 2
and 3. Together, these results have demonstrated evidence for
the occurrence of autophagy during cisplatin-induced renal
cell injury.
Effects of p53 inhibition on cisplatin-induced autophagy
We and others have demonstrated a role for p53 in cisplatin-
induced renal cell apoptosis in vitro and nephrotoxicity
in vivo.13,15,17,18,24,36,38 Interestingly, a recent study by
Feng et al.39 suggests that p53 may also be involved in the
regulation of autophagy. We, therefore, tested the effects of
pifithrin-a (PF), a pharmacological inhibitor of p53, on
cisplatin-induced autophagy in RPTCs. For this purpose,
cells were transfected with GFP-LC3 and then incubated with
20 mM cisplatin in the presence of 20 mM PF. As shown in
Figure 4a, cisplatin incubation for 6 h induced punctate
GFP-LC3 in 56% of the cells, which was suppressed to 36%
by PF. In addition, PF induced an interesting distribution
pattern of punctate LC-GFP in the autophagic cells. As shown
in Figure 4b, the autophagic cells in the cisplatinþ PF group
had many big empty vacuoles surrounded by punctate
GFP-LC3 staining. We further collected cell lysates for
immunoblot analysis of LC3 (Figure 4c). Consistently, PF
had partial inhibitory effects on LC3-II formation during
cisplatin treatment (Figure 4c and d). Together, these results
suggest the involvement of p53 in triggering autophagy
during cisplatin treatment of renal tubular cells.
Effects of Bcl-2 on cisplatin-induced autophagy
Bcl-2 is well known for its antiapoptotic activity. Interest-
ingly, recent studies have shown that Bcl-2 is also an anti-
autophagic protein,40 which binds and sequesters Beclin-1 to
prevent vesicle nucleation, an early step of autophagosome
formation. To determine the regulation of cisplatin-induced
autophagy by Bcl-2, we used an RPTC line stably transfected
with Bcl-2 that was established in our previous work.41 Wild-
type RPTCs and Bcl-2-transfected cells were incubated with
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20 mM cisplatin for 6 h. In wild-type RPTCs, cisplatin
treatment increased autophagic cells to 57%, while no
increase was shown in Bcl-2 cells (Figure 5a). Examination
of GFP-LC3 signal at later time points did not reveal
significant amounts of autophagic cells in the Bcl-2 group
either (Figure 5b). We further analyzed LC3 by immunoblots.
Consistent with earlier results (Figure 1), cisplatin induced
LC3-II with a maximal accumulation at 6 h; such induction
was not shown in Bcl-2 cells (Figure 5c and d). Together, the
results demonstrate an impressive inhibitory effects of Bcl-2
on cisplatin-induced autophagy.
Effects of 3-methyladenine and bafilomycin on autophagy
during cisplatin treatment
Depending on the experimental conditions, autophagy can
be cell killing or cytoprotective.2,42 What is the pathophy-
siological role of autophagy during cisplatin-induced tubular
cell injury? To address this question, we determined the
effects of 3-methyladenine (3-MA) and bafilomycin (BAF),
two pharmacological inhibitors of autophagy. We first
verified their effects on autophagy. As shown in Figures 6a,
3-MA blocked GFP-LC3 redistribution into punctate form.
In stark contrast, BAF enhanced formation of punctate LC3.
The results were further supported by cell count (Figure 6b).
The opposite effects of 3-MA and BAF on LC3 distribution
are not surprising, as these two inhibitors block autophagy at
different levels: while 3-MA inhibits the initiation of
autophagosome, BAF attenuates fusion of autophagosome
with lysosome.42 As a result, 3-MA blocked autophagosome
formation from the beginning, whereas BAF prevented
degradation of GFP-LC3 in autophagolysosomes and in turn
increased LC3 punctate. This notion was also supported by
our immunoblot analysis of LC3 (Figure 6c and d). 3-MA
blocked the formation LC3-II in cisplatin-treated as well as in
control cells, while BAF preserved LC3-II during cisplatin
treatment even at 24 h.
3-MA and BAF enhance apoptosis during cisplatin treatment
After confirming the effects of 3-MA and BAF on autophagy,
we examined their effects on apoptosis during cisplatin
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Figure 1 | Cisplatin-induced autophagy in renal proximal tubular cells. (a) The time course of cisplatin-induced LC3 punctate formation.
RPTCs transiently transfected with GFP-LC3 were incubated with 20 mM cisplatin for 0–16 h. The percentage of cells with punctate GFP-LC3
staining was determined by fluorescence microscopy. (b) Representative cell images showing punctate GFP-LC3 distribution after cisplatin
treatment. RPTCs transiently transfected with GFP-LC3 were incubated with or without 20 mM cisplatin for 6 h and then examined by
confocal microscopy. (c) Dose dependence of cisplatin-induced punctate LC3 staining. RPTCs transiently transfected with GFP-LC3 were
incubated with 0–20 mM cisplatin for 6 h and then examined by fluorescence microscopy to determine the percentage of cells with punctate
GFP-LC3 staining. (d) LC3-II formation during cisplatin treatment. RPTCs were incubated with 20 mM cisplatin for 0–16 h to collect whole-cell
lysates for immunoblot analysis of LC3 and also b-actin as a protein loading control. (e) The time course of cisplatin-induced apoptosis.
Apoptosis was assessed by morphological methods. Data in (a, c, e) are expressed as mean±s.d. (n¼ 4); *, statistically significantly different
from the control group without cisplatin treatment. Data in panels b and d are representative of at least four separate experiments. The
results show that cisplatin dose and time dependently induced autophagy, prior to occurrence of apoptosis.
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treatment. Apoptosis was evaluated based on cellular and
nuclear morphology. As shown in Figure 7a, control cells
without cisplatin exposure appeared healthy. Incubation with
20 mM cisplatin for 12 h induced apoptosis in some cells,
which had a shrunken cell body with condensed and
fragmented nuclei. Many of these cells also showed formation
of apoptotic bodies or blebs. Importantly, addition of
either 3-MA or BAF significantly increased apoptosis
during cisplatin incubation (Figure 7). Quantification by cell
count indicated that 3-MA and BAF increased apoptosis
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Figure 2 | Electron microscopic analysis of autophagy. RPTCs were incubated with or without 20 mM cisplatin for 6 h. The cells were then
fixed and processed for electron microscopy. (a) Representative electron micrographs showing autophagosomes and autophagic vesicles
in cisplatin-treated cells. Arrows, autophagosomes; arrowheads, autophagic vesicles. (b) Quantification of autophagic vesicles. The number
of autophagic vesicles per 100 mm2 was determined in electron micrographs. Data are expressed as means±s.d. (n¼ 4); *, statistically
significantly different from the control cells. (c–g) Selected micrographs showing the assembly and progression of autophagic vesicles.
(c) sequestration of cytoplasm by pre-autophagasome; (d) close contact of autophagosome with lysosome; (e) docking and fusion of
autophagosome with lysosome; (f) typical autophagosome containing cytosol; (g) typical autophagosome containing organelles.
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Figure 3 | Autophagy in renal tissues during cisplatin nephrotoxicity in vivo. C57BL/6 mice (male, 8–10 weeks old) were injected with
30 mg/kg cisplatin. At the indicated time points, renal cortical tissues were collected for electron microscopy or homogenized for
immunoblot analysis of LC3. (a) Electron micrograph of representative cells. (b) Quantification of tubular cells with autophagic vacuoles or
vesicles. Autophagic cells were identified by the presence of numerous autophagic vacuoles, vesicles, or autophagosomes. Over 100
proximal tubular cells from 2–3 animals were evaluated for each time point. (c) Immunoblot of LC3. Shown are representative blots of four
separate experiments.
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from 27% to 47 and 55%, respectively (Figure 7b). We
further examined the effects of 3-MA on apoptosis induced
by lower concentrations of cisplatin. As shown in Figure 7c,
5 mM cisplatin incubation for 16 h induced B3% apoptosis,
which was increased to B20% by 3-MA. Together, the
pharmacological results suggest that autophagy might be a
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(b) Representative images of GFP-LC3 distribution in control, cisplatin-treated, and cisplatinþ PF-treated cells. (c) Immunoblot analysis
of LC3-II accumulation. The blots are representative of at least three separate experiments. (d) Densitometry of LC3-II signals in
immunoblots. The results show that cisplatin-induced autophagy was partially suppressed by PF, a p53 inhibitor.
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Figure 5 | Effects of Bcl-2 expression on cisplatin-induced autophagy. Wild type and Bcl-2-transfected RPTCs were analyzed in parallel.
(a) Cisplatin-induced punctate GFP-LC3 distribution. The cells were transiently transfected with GFP-LC3, and incubated with 20 mM cisplatin
for 6 h for microscopic evaluation. (b) Representative images of GFP-LC3 distributions in Bcl-2 cells during cisplatin treatment.
(c) Immunoblot analysis of LC3 accumulation. The blots were then reprobed for b-actin to monitor protein loading and transferring.
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different from the control group without cisplatin treatment. Data in panels b–d are representative of at least three separate experiments.
The results show that cisplatin-induced autophagy was diminished by Bcl-2 expression.
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cytoprotective mechanism against apoptosis during cisplatin
treatment.
Knockdown of Beclin-1 sensitizes cells to cisplatin-induced
apoptosis
To further determine the role of autophagy in cell death or
survival during cisplatin treatment, we used short-hairpin
RNA (shRNA) to knock down Beclin-1, a critical protein
involved in initial autophagic vesicle formation.5,42 The
transfection efficacy was relatively low for RPTCs; thus,
human embryonic kidney (HEK) cells were initially used for
the shRNA study. Four Beclin-1 shRNAs and one non-
targeting control shRNA was first tested for their effects on
Beclin-1 expression. As shown in Figure 8a, both #3 and #4
Beclin shRNA significantly attenuated Beclin-1 expression.
We then examined the effects of Beclin shRNA#4 on
cisplatin-induced autophagy. As expected, transfection with
#4, but not the non-targeting control shRNA, blocked
autophagic GFP-LC3 distribution during cisplatin treatment
(Figure 8b). Importantly, Beclin shRNA sensitized the cells to
cisplatin-induced apoptosis. As shown in Figure 8c, cisplatin
induced 20% apoptosis, which was increased to 53% by
shRNA knockdown of Beclin-1. As a control, the non-
targeting shRNA did not have significant effects. We further
examined the effects of Beclin knockdown in RPTCs.
The shRNA constructs used in our study also had GFP
sequence and expressed the fluorescent protein. Thus, RPTCs
were transfected with control or Beclin shRNA and then
treated with cisplatin. The transfected cells with GFP were
specifically analyzed for apoptosis. The results are shown in
Figure 8d. While the group transfected with control shRNA
had 32% apoptosis, the cells transfected with Beclin shRNA
had 52%. Together with the pharmacological results of 3-MA
and BAF, the shRNA study has provided strong evidence
that autophagy during cisplatin-induced renal injury is an
important mechanism for cytoprotection and cell survival.
DISCUSSION
Autophagy has been intensely studied during the past a few
years.1–4 Over 30 Atg genes have been discovered in yeast and
their mammalian orthologs are being identified. Importantly,
it is now becoming clear that autophagy is a general cellular
response to stress, not limited only to nutrient deprivation or
starvation. Intriguingly, autophagy can be cell killing or
cytoprotective, although it is largely unknown what deter-
mine the final outcomes.2,42 Despite the rapid progress in
autophagy research, very little is known about autophagy, its
regulation, and pathophysiological role(s) in kidney cells and
tissues. This study has demonstrated compelling evidence for
the occurrence of autophagy in an experimental model of
renal injury. Importantly, we show that autophagy is a
cytoprotective mechanism for cell survival under the
pathogenic conditions.
The majority of experiments in this study were conducted
in an in vitro model, where cultured renal proximal tubular
cells were incubated with cisplatin to induce cell stress, injury,
and death. This model has been used and characterized in
our previous studies.16–18,43 This study has demonstrated the
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occurrence of autophagy in this model by using multiple
techniques, including examination of autophagic or punctate
GFP-LC3, immunoblot analysis of LC3-II formation, and
electron microscopic detection of autophagosomes. Com-
pared with these cell culture results, the in vivo evidence of
autophagy is limited, due to technical difficulties of in vivo
analysis. Nevertheless, by electron microscopy we have
demonstrated an increase of autophagic cells during cisplatin
nephrotoxicity in C57BL/6 mice. In addition, we have shown
accumulation of LC3-II, the autophagic form of LC3, in renal
tissues during in vivo cisplatin nephrotoxicity (Figure 3).
In the in vitro model, we show that autophagy occurs
within hours of cisplatin incubation, whereas significant
apoptosis is not induced until 12 h (Figure 1). The earlier
occurrence of autophagy suggests that it is not caused by, or
secondary to, apoptosis. Then, does autophagy contribute to
later development of apoptosis in the model system? The
answer is, No. As a matter of fact, inhibition of autophagy by
using pharmacological and gene-knockdown approaches
enhances apoptosis (Figures 7 and 8), suggesting that
autophagy during cisplatin treatment is not a cell killing,
but a pro-survival, mechanism. Examination of the dose
dependence of cisplatin-induced autophagy indicates that
autophagy is induced by 5 mM cisplatin (Figure 1b), a
concentration that does not induce significant apoptosis in
RPTCs (Figure 7c). Thus, in this model, occurrence of
autophagy and apoptosis depends on the severity of the
injury or stress: autophagy can be induced by mild to
moderate stress, whereas apoptosis requires more severe
stress.
Mechanistically, we show that cisplatin-induced auto-
phagy is partially inhibited by PF, suggesting a role for p53 in
autophagy under the experimental condition. Our previous
work has shown that p53 is activated early during cisplatin
treatment of RPTCs.16,17 p53 Phosphorylation is induced
within 30 min of cisplatin incubation, which is followed by
p53 stabilization and accumulation in 2–4 h. The time course
of p53 activation is consistent with its involvement in
autophagy, which occurs within hours of cisplatin incuba-
tion. A previous study by Feng et al.39 has suggested a
regulation of autophagy by p53. Following activation, p53
can inactivate mammalian target of rapamycin via AMPK,
leading to autophagy. Whether the same p53-signaling
pathway mediates autophagy during cisplatin treatment of
renal tubular cells, remains to be determined. Interestingly,
our previous work has established a role for p53 in tubular
cell apoptosis and renal injury induced by cisplatin.17,18,36
Therefore, p53 can initiate the cell survival (autophagy) as
well as the cell death (apoptosis)-signaling cascade. It is
intriguing how the same molecule accomplishes two
apparently opposite tasks and what determines the final
outcome.
Another important autophagy regulator identified in this
study is Bcl-2. Bcl-2 is well recognized as an antiapoptotic
protein. However, stable expression of Bcl-2 can almost
completely block the occurrence of autophagy during
cisplatin incubation (Figure 5). The inhibitory effects of
Bcl-2 are shown not only at early time points, but also at
later time points of 24 h of cisplatin treatment (Figure 5).
In previous studies, Bcl-2 has been proposed to inhibit
autophagy by binding to Beclin-1. Bcl-2 binding of Beclin-1
may disrupt the protein complex (involving Beclin-1,
UVRAG, vps15, and others) that is critical to vesicle
nucleation, the start point of autophagosome formation.40
While this is a tantalizing possibility, our preliminary
experiments do not show a clear-cut Bcl-2/Beclin-1 interac-
tion in co-immunoprecipitation assay (not shown). In
addition to Beclin-1 binding, Bcl-2 may suppress autophagy
by other indirect mechanisms. For example, the latest work
by Hoyer-Hansen et al.44 suggests that calcium release from
endoplasmic reticulum during cell stress can activate Ca2þ /
calmodulin-dependent kinases and AMPK, leading to
inhibition of mammalian target of rapamycin and conse-
quent activation of autophagy. Bcl-2 may suppress autophagy
by diminishing calcium release in stressed cells. In line with
this scenario, Bcl-2 localized to endoplasmic reticulum is
inhibitory to autophagy, whereas mitochondrially targeted
Bcl-2 inhibits only apoptosis but not autophagy.44 Further
investigations should test these interesting possibilities to
gain insights into the autophagy regulation during cisplatin
nephrotoxicity.
Functionally, our data suggest that autophagy is cytopro-
tective during cisplatin-induced renal cell injury. This
conclusion is supported not only by the pharmacological
experiments using 3-MA and BAF, but also by the Beclin-1
shRNA results. It is noteworthy that 3-MA and BAF block
autophagy at up- and downstream levels, respectively.42
3-MA inhibits the autophagy-specific class-III phosphatidyl-
inositol 3- kinase, which is crucial to vesicle nucleation
or formation of pre-autophagasome, a very early event of
autophagy. The same step is targeted by gene knockdown of
Beclin-1. As a result, both 3-MA and Beclin-1 shRNA prevent
punctate GFP-LC3 localization in autophagosome as well as
LC3-II formation. In contrast, BAF inhibits fusion of
lysosome with autophagosome, a late event in autophagy
for final degradation of autophagocytosed materials. Thus,
BAF does not prevent LC3 changes (Figure 6) in spite of its
inhibitory effects on autophagy. What is important to
recognize is that, regardless of the targeting steps (early or
late) and approaches (pharmacological or genetic), inhibition
of autophagy exacerbates apoptosis during cisplatin treat-
ment (Figures 7 and 8). Certainly, such a conclusion needs to
be further validated by in vivo studies using specific Atg-
knockout models. The mechanism underlying pro-survival
role of autophagy is largely unknown. Obviously, under
conditions of starvation or nutrient deprivation, autophagy
can prolong cell survival by self-digesting to sustain the basal
energy demand of viability. In response to other types of
stress, autophagy may remove or clean up the damaged
macromolecules and subcellular organelles. In addition, we
speculate that signaling activated during autophagy may
interfere with cell death pathways. Further investigation
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should focus on these possibilities to gain insights into the
pathophysiological role of autophagy.
MATERIALS AND METHODS
Materials
RPTC, a rat kidney proximal tubular cell line, was originally
obtained from Dr Hopfer (Case Western Reserve University,
Cleveland, OH, USA). The cells were transfected with Bcl-2 to
generate a stable Bcl-2-expressing cell line.41 The cells were
maintained and plated for experiments as described previously.18
HEK cells were purchased from ATCC and maintained in minimal
essential medium supplemented with 10% horse serum, glutamine,
and antibiotics. C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, ME, USA).
Antibodies were from the following sources: anti-LC3 from
Dr Noboru Mizushima (Tokyo Metropolitan Institute of Medical
Science, Tokyo, Japan), anti-Beclin-1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-b-actin (Sigma, St Louis, MO, USA),
secondary antibodies (Jackson ImmunoResearch, West Grove, PA,
USA). PF was purchased from Calbiochem (San Diego, CA, USA).
Other reagents, including cisplatin, 3-methyladenine, and BAF-A1,
were from purchased from Sigma.
Models of cisplatin injury
For in vitro experiments, cisplatin was added to RPTCs or HEK cells
in culture medium at the indicated concentrations as previously.16–18
For in vivo experiments, male C57Bl/6 mice of 8–10 weeks were
injected with a single dose (30 mg/kg body weight) of cisplatin as in
our recent studies.36,38 Renal function was monitored by measuring
blood urea nitrogen and creatinine level. Renal tissues were collected
at different time points for analysis. The animal protocol was
approved by the Institutional Animal Care and Use Committees of
Medical College of Georgia and VA Medical Center at Augusta.
Analysis of GFP-LC3 redistribution
The GFP-LC3 plasmid was a generous gift from Dr Yoshimori
(National Institute of Genetics, Mishima, Japan) and was used
recently to detect autophagy.45 Transfection was conducted as
detailed recently.46 Briefly, cells were plated on a coverslip to reach
B50% confluence for transfection with 1 mg of plasmids by using
Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA). The cells
were then maintained in culture medium for 24 h to reach 80–90%
confluence for cisplatin treatment. At the end of incubation, cells
were fixed with 4% paraformaldehyde and examined by fluorescence
microscopy to count the cells with punctate GFP-LC3. Cell images
were also collected by confocal microscopy as described.46
shRNA knockdown of Beclin-1
SureSilencing shRNA plasmids for Beclin-1 (Rat Becn1) were purchased
from SuperArray (Frederick, MD, USA). A non-targeting shRNA was
used as a control. Cells at B50% confluence were transfected with
various shRNA plasmids by using Lipofectamine 2000 reagent
(Invitrogen). After transfection, cells were maintained in culture medium
for 24 h to reach 80–90% confluence for cisplatin treatment or to collect
whole-cell lysates for immunoblot analysis of Beclin-1.
Morphological examination of apoptosis
Apoptosis was evaluated by morphological criteria as described
previously.16,17,46.Typical apoptotic morphology included cellular
shrinkage, nuclear condensation and fragmentation, and formation
of apoptotic bodies. Briefly, at the end of the experiment, cells were
stained with 10 mg/ml of Hoechst 33342. Cellular and nuclear
morphology were then examined by phase-contrast and fluorescence
microscopy. For cell count, four fields withB200 cells per field were
evaluated in each dish to estimate the percentage of cells with typical
apoptotic morphology.
Immunoblot analysis
As described previously,16,17,46 whole-cell or tissue lysates were
homogenized in 2% SDS buffer. The same amounts of protein
(usually 25 g, determined with the BCA reagent from Pierce
Chemical (Rockford, IL, USA)) were loaded for each lane for
reducing electrophoresis. The resolved proteins were then electro-
blotted onto polyvinylidene difluoride membranes. The blots were
incubated in a blocking buffer with 1% bovine serum albumin and
2% fat-free milk, and exposed to the primary antibodies overnight
at 4 1C, and finally incubated with the horseradish peroxidase-
conjugated secondary antibody to reveal antigens using an enhanced
chemiluminescence kit from Pierce.
Electron microscopy
Renal tissues or cells were fixed at room temperature with a fixative
containing 2.5% glutaraldehyde, 1% formaldehyde, 100 mM sodium
phosphate, pH 7.2. The samples were then post-fixed in 1% osmium
tetroxide, processed by standard procedures, and examined with a
JEOL 1010 transmission electron microscope. In renal tissues, cells
with high numbers of autophagic vacuoles or vesicles were counted
in micrographs. In cultured cells, quantification of autophagic
vesicles was performed as described previously.45
Statistics
Data were expressed as means±s.d. (nX4). Statistical differences
between two groups were determined by Student’s t-test with
Microsoft EXCEL 2002. For comparison of multiple groups, analysis
of variance with a post hoc test was conducted. Po0.05 was
considered to reflect significant differences.
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